A new review concludes that basal insulin analogs used in patients with type 2 diabetes do not differ substantially in their glucose-lowering effect.

Conclusive evidence about the comparative efficacy of the many available basal insulins has been lacking. This meta-analysis and systematic review, based on 39 trials involving 10 basal insulin analogs, was meant to fill that gap.

свернуть